항암제 부작용 제어 후보물질인 나프토퀴논계 화합물은 현재 식약의약품안전처 임상시험 승인 심사 중이다.
Naphthoquinone compounds, a candidate substance for controlling side effects of anticancer drugs, are currently under review for approval of clinical trials by the Ministry of Food and Drug Safety.